Which has better earnings & valuation, PMVP or AGMB?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PMV Pharmaceuticals N/A N/A -$77.74M -$1.42 N/A AgomAb Therapeutics N/A N/A -$70.77M N/A N/A

Is PMVP or AGMB more profitable?

AgomAb Therapeutics' return on equity of 0.00% beat PMV Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets PMV Pharmaceuticals N/A -78.11% -70.13% AgomAb Therapeutics N/A N/A N/A

Does the media prefer PMVP or AGMB?

In the previous week, AgomAb Therapeutics had 11 more articles in the media than PMV Pharmaceuticals. MarketBeat recorded 14 mentions for AgomAb Therapeutics and 3 mentions for PMV Pharmaceuticals. AgomAb Therapeutics' average media sentiment score of 1.53 beat PMV Pharmaceuticals' score of -0.83 indicating that AgomAb Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PMV Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative AgomAb Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts prefer ELYM or PMVP?

PMV Pharmaceuticals has a consensus price target of $4.33, suggesting a potential upside of 185.09%. Given PMV Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe PMV Pharmaceuticals is more favorable than Eliem Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 PMV Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80

Which has higher valuation and earnings, ELYM or PMVP?

Eliem Therapeutics is trading at a lower price-to-earnings ratio than PMV Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eliem Therapeutics N/A N/A -$35.12M -$0.53 N/A PMV Pharmaceuticals N/A N/A -$77.74M -$1.42 N/A

Is ELYM or PMVP more profitable?

Eliem Therapeutics' return on equity of -47.03% beat PMV Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Eliem Therapeutics N/A -47.03% -45.97% PMV Pharmaceuticals N/A -78.11% -70.13%

Which has stronger earnings and valuation, BNTC or PMVP?

Benitec Biopharma is trading at a lower price-to-earnings ratio than PMV Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Benitec Biopharma N/A N/A -$45.55M -$0.98 N/A PMV Pharmaceuticals N/A N/A -$77.74M -$1.42 N/A

Is BNTC or PMVP more profitable?

Benitec Biopharma's return on equity of -28.41% beat PMV Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Benitec Biopharma N/A -28.41% -27.76% PMV Pharmaceuticals N/A -78.11% -70.13%

Does the media favor BNTC or PMVP?

In the previous week, Benitec Biopharma and Benitec Biopharma both had 3 articles in the media. Benitec Biopharma's average media sentiment score of 0.37 beat PMV Pharmaceuticals' score of -0.83 indicating that Benitec Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Benitec Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PMV Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative

Is PRLD or PMVP more profitable?

Prelude Therapeutics' return on equity of -75.35% beat PMV Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Prelude Therapeutics N/A -75.35% -44.39% PMV Pharmaceuticals N/A -78.11% -70.13%

Do analysts prefer PMVP or INDP?

PMV Pharmaceuticals presently has a consensus price target of $4.33, indicating a potential upside of 185.09%. Given PMV Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe PMV Pharmaceuticals is more favorable than Indaptus Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PMV Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80 Indaptus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, PMVP or INDP?

PMV Pharmaceuticals is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PMV Pharmaceuticals N/A N/A -$77.74M -$1.42 N/A Indaptus Therapeutics N/A N/A -$20.85M -$6.33 N/A

Is PMVP or INDP more profitable?

PMV Pharmaceuticals' return on equity of -78.11% beat Indaptus Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets PMV Pharmaceuticals N/A -78.11% -70.13% Indaptus Therapeutics N/A -302.89% -203.49%

PMV Pharmaceuticals (PMVP) Competitors

$1.52 +0.03 (+2.01%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$1.56 +0.04 (+2.89%)

As of 10/9/2026 07:30 PM Eastern

Compare

PMVP vs. AGMB, ELYM, BNTC, PRLD, and INDP

Should you buy PMV Pharmaceuticals stock or one of its competitors? PMV Pharmaceuticals's main competitors and comparable companies include AgomAb Therapeutics (AGMB), Eliem Therapeutics (ELYM), Benitec Biopharma (BNTC), Prelude Therapeutics (PRLD), and Indaptus Therapeutics (INDP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does PMV Pharmaceuticals compare to AgomAb Therapeutics?

PMV Pharmaceuticals (NASDAQ:PMVP) and AgomAb Therapeutics (NASDAQ:AGMB) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings.

In the previous week, AgomAb Therapeutics had 11 more articles in the media than PMV Pharmaceuticals. MarketBeat recorded 14 mentions for AgomAb Therapeutics and 3 mentions for PMV Pharmaceuticals. AgomAb Therapeutics' average media sentiment score of 1.53 beat PMV Pharmaceuticals' score of -0.83 indicating that AgomAb Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PMV Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative
AgomAb Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

PMV Pharmaceuticals presently has a consensus target price of $4.33, indicating a potential upside of 185.09%. AgomAb Therapeutics has a consensus target price of $37.50, indicating a potential upside of 313.00%. Given AgomAb Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe AgomAb Therapeutics is more favorable than PMV Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PMV Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

90.2% of PMV Pharmaceuticals shares are held by institutional investors. 10.2% of PMV Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

AgomAb Therapeutics' return on equity of 0.00% beat PMV Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PMV Pharmaceuticals	N/A	-78.11%	-70.13%
AgomAb Therapeutics	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PMV Pharmaceuticals	N/A	N/A	-$77.74M	-$1.42	N/A
AgomAb Therapeutics	N/A	N/A	-$70.77M	N/A	N/A

Summary

AgomAb Therapeutics beats PMV Pharmaceuticals on 8 of the 11 factors compared between the two stocks.

How does PMV Pharmaceuticals compare to Eliem Therapeutics?

Eliem Therapeutics (NASDAQ:ELYM) and PMV Pharmaceuticals (NASDAQ:PMVP) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

Eliem Therapeutics is trading at a lower price-to-earnings ratio than PMV Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A
PMV Pharmaceuticals	N/A	N/A	-$77.74M	-$1.42	N/A

Eliem Therapeutics' return on equity of -47.03% beat PMV Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eliem Therapeutics	N/A	-47.03%	-45.97%
PMV Pharmaceuticals	N/A	-78.11%	-70.13%

In the previous week, PMV Pharmaceuticals had 3 more articles in the media than Eliem Therapeutics. MarketBeat recorded 3 mentions for PMV Pharmaceuticals and 0 mentions for Eliem Therapeutics. Eliem Therapeutics' average media sentiment score of 0.00 beat PMV Pharmaceuticals' score of -0.83 indicating that Eliem Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Eliem Therapeutics	Neutral
PMV Pharmaceuticals	Negative

69.8% of Eliem Therapeutics shares are held by institutional investors. Comparatively, 90.2% of PMV Pharmaceuticals shares are held by institutional investors. 4.7% of Eliem Therapeutics shares are held by insiders. Comparatively, 10.2% of PMV Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Eliem Therapeutics has a beta of -0.39, suggesting that its share price is 139% less volatile than the broader market. Comparatively, PMV Pharmaceuticals has a beta of 1.36, suggesting that its share price is 36% more volatile than the broader market.

PMV Pharmaceuticals has a consensus price target of $4.33, suggesting a potential upside of 185.09%. Given PMV Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe PMV Pharmaceuticals is more favorable than Eliem Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
PMV Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Summary

PMV Pharmaceuticals beats Eliem Therapeutics on 9 of the 14 factors compared between the two stocks.

How does PMV Pharmaceuticals compare to Benitec Biopharma?

Benitec Biopharma (NASDAQ:BNTC) and PMV Pharmaceuticals (NASDAQ:PMVP) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership.

Benitec Biopharma is trading at a lower price-to-earnings ratio than PMV Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Benitec Biopharma	N/A	N/A	-$45.55M	-$0.98	N/A
PMV Pharmaceuticals	N/A	N/A	-$77.74M	-$1.42	N/A

Benitec Biopharma has a beta of 0.25, suggesting that its stock price is 75% less volatile than the broader market. Comparatively, PMV Pharmaceuticals has a beta of 1.36, suggesting that its stock price is 36% more volatile than the broader market.

Benitec Biopharma presently has a consensus price target of $24.00, suggesting a potential upside of 170.57%. PMV Pharmaceuticals has a consensus price target of $4.33, suggesting a potential upside of 185.09%. Given PMV Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe PMV Pharmaceuticals is more favorable than Benitec Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Benitec Biopharma	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
PMV Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Benitec Biopharma's return on equity of -28.41% beat PMV Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Benitec Biopharma	N/A	-28.41%	-27.76%
PMV Pharmaceuticals	N/A	-78.11%	-70.13%

In the previous week, Benitec Biopharma and Benitec Biopharma both had 3 articles in the media. Benitec Biopharma's average media sentiment score of 0.37 beat PMV Pharmaceuticals' score of -0.83 indicating that Benitec Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Benitec Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PMV Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative

52.2% of Benitec Biopharma shares are owned by institutional investors. Comparatively, 90.2% of PMV Pharmaceuticals shares are owned by institutional investors. 4.8% of Benitec Biopharma shares are owned by insiders. Comparatively, 10.2% of PMV Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

PMV Pharmaceuticals beats Benitec Biopharma on 7 of the 13 factors compared between the two stocks.

How does PMV Pharmaceuticals compare to Prelude Therapeutics?

Prelude Therapeutics (NASDAQ:PRLD) and PMV Pharmaceuticals (NASDAQ:PMVP) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and media sentiment.

79.7% of Prelude Therapeutics shares are held by institutional investors. Comparatively, 90.2% of PMV Pharmaceuticals shares are held by institutional investors. 49.2% of Prelude Therapeutics shares are held by insiders. Comparatively, 10.2% of PMV Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Prelude Therapeutics currently has a consensus price target of $8.75, suggesting a potential upside of 124.94%. PMV Pharmaceuticals has a consensus price target of $4.33, suggesting a potential upside of 185.09%. Given PMV Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe PMV Pharmaceuticals is more favorable than Prelude Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
PMV Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Prelude Therapeutics' return on equity of -75.35% beat PMV Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prelude Therapeutics	N/A	-75.35%	-44.39%
PMV Pharmaceuticals	N/A	-78.11%	-70.13%

Prelude Therapeutics has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, PMV Pharmaceuticals has a beta of 1.36, indicating that its share price is 36% more volatile than the broader market.

In the previous week, PMV Pharmaceuticals had 2 more articles in the media than Prelude Therapeutics. MarketBeat recorded 3 mentions for PMV Pharmaceuticals and 1 mentions for Prelude Therapeutics. Prelude Therapeutics' average media sentiment score of -0.71 beat PMV Pharmaceuticals' score of -0.83 indicating that Prelude Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Prelude Therapeutics	Negative
PMV Pharmaceuticals	Negative

PMV Pharmaceuticals has lower revenue, but higher earnings than Prelude Therapeutics. Prelude Therapeutics is trading at a lower price-to-earnings ratio than PMV Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prelude Therapeutics	$12.14M	25.57	-$99.50M	-$0.73	N/A
PMV Pharmaceuticals	N/A	N/A	-$77.74M	-$1.42	N/A

Summary

PMV Pharmaceuticals beats Prelude Therapeutics on 8 of the 15 factors compared between the two stocks.

How does PMV Pharmaceuticals compare to Indaptus Therapeutics?

PMV Pharmaceuticals (NASDAQ:PMVP) and Indaptus Therapeutics (NASDAQ:INDP) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation.

PMV Pharmaceuticals presently has a consensus price target of $4.33, indicating a potential upside of 185.09%. Given PMV Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe PMV Pharmaceuticals is more favorable than Indaptus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PMV Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, PMV Pharmaceuticals had 2 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 3 mentions for PMV Pharmaceuticals and 1 mentions for Indaptus Therapeutics. Indaptus Therapeutics' average media sentiment score of 0.00 beat PMV Pharmaceuticals' score of -0.83 indicating that Indaptus Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
PMV Pharmaceuticals	Negative
Indaptus Therapeutics	Neutral

PMV Pharmaceuticals' return on equity of -78.11% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PMV Pharmaceuticals	N/A	-78.11%	-70.13%
Indaptus Therapeutics	N/A	-302.89%	-203.49%

90.2% of PMV Pharmaceuticals shares are held by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are held by institutional investors. 10.2% of PMV Pharmaceuticals shares are held by company insiders. Comparatively, 9.9% of Indaptus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

PMV Pharmaceuticals has a beta of 1.36, indicating that its stock price is 36% more volatile than the broader market. Comparatively, Indaptus Therapeutics has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market.

PMV Pharmaceuticals is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PMV Pharmaceuticals	N/A	N/A	-$77.74M	-$1.42	N/A
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$6.33	N/A

Summary

PMV Pharmaceuticals beats Indaptus Therapeutics on 11 of the 14 factors compared between the two stocks.

Get PMV Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PMVP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PMVP vs. The Competition

Export

Metric	PMV Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$79.65M	$3.85B	$7.16B	$13.21B
Dividend Yield	N/A	3.66%	2.53%	16.37%
P/E Ratio	-1.07	13.62	275.30	26.16
Price / Sales	N/A	1,234.33	635.97	107.50
Price / Cash	N/A	116.56	76.38	53.09
Price / Book	0.77	17.17	11.22	6.33
Net Income	-$77.74M	-$22.69M	$3.50B	$382.15M
7 Day Performance	-15.08%	-1.34%	-0.89%	-1.40%
1 Month Performance	5.56%	-8.45%	-4.42%	-3.47%
1 Year Performance	12.59%	14.02%	7.03%	1.18%

PMV Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PMVP PMV Pharmaceuticals	3.2764 of 5 stars	$1.52 +2.0%	$4.33 +185.1%	+9.4%	$79.65M	N/A	N/A	54	Positive News
AGMB AgomAb Therapeutics	3.9369 of 5 stars	$9.22 +4.8%	$37.50 +306.7%	N/A	$318.88M	N/A	N/A	62	News Coverage Positive News
ELYM Eliem Therapeutics	N/A	$10.71 +0.3%	N/A	+503.3%	$318.64M	N/A	N/A	9
BNTC Benitec Biopharma	2.6996 of 5 stars	$8.75 -2.7%	$24.00 +174.3%	-37.5%	$313.60M	N/A	N/A	24	Analyst Forecast
PRLD Prelude Therapeutics	2.3936 of 5 stars	$3.88 +1.3%	$8.75 +125.5%	+177.9%	$305.65M	$12.14M	N/A	79

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PMVP) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PMV Pharmaceuticals (PMVP) Competitors

PMVP vs. AGMB, ELYM, BNTC, PRLD, and INDP

How does PMV Pharmaceuticals compare to AgomAb Therapeutics?

Summary

How does PMV Pharmaceuticals compare to Eliem Therapeutics?

Summary

How does PMV Pharmaceuticals compare to Benitec Biopharma?

Summary

How does PMV Pharmaceuticals compare to Prelude Therapeutics?

Summary

How does PMV Pharmaceuticals compare to Indaptus Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PMVP vs. The Competition

PMV Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PMV Pharmaceuticals (PMVP) Competitors

PMVP vs. AGMB, ELYM, BNTC, PRLD, and INDP

How does PMV Pharmaceuticals compare to AgomAb Therapeutics?

Does the media prefer PMVP or AGMB?

Do analysts prefer PMVP or AGMB?

Do insiders & institutionals believe in PMVP or AGMB?

Is PMVP or AGMB more profitable?

Which has better earnings & valuation, PMVP or AGMB?

Summary

How does PMV Pharmaceuticals compare to Eliem Therapeutics?

Which has higher valuation and earnings, ELYM or PMVP?

Is ELYM or PMVP more profitable?

Does the media favor ELYM or PMVP?

Do institutionals & insiders hold more shares of ELYM or PMVP?

Which has more volatility & risk, ELYM or PMVP?

Do analysts prefer ELYM or PMVP?

Summary

How does PMV Pharmaceuticals compare to Benitec Biopharma?

Which has stronger earnings and valuation, BNTC or PMVP?

Which has more volatility and risk, BNTC or PMVP?

Do analysts recommend BNTC or PMVP?

Is BNTC or PMVP more profitable?

Does the media favor BNTC or PMVP?

Do institutionals & insiders hold more shares of BNTC or PMVP?

Summary

How does PMV Pharmaceuticals compare to Prelude Therapeutics?

Do institutionals and insiders have more ownership in PRLD or PMVP?

Do analysts recommend PRLD or PMVP?

Is PRLD or PMVP more profitable?

Which has more volatility & risk, PRLD or PMVP?

Does the media favor PRLD or PMVP?

Which has preferable earnings and valuation, PRLD or PMVP?

Summary

How does PMV Pharmaceuticals compare to Indaptus Therapeutics?

Do analysts prefer PMVP or INDP?

Does the media refer more to PMVP or INDP?

Is PMVP or INDP more profitable?

Do insiders and institutionals believe in PMVP or INDP?

Which has more risk & volatility, PMVP or INDP?

Which has better earnings and valuation, PMVP or INDP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PMVP vs. The Competition

PMV Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools